Research notes & guides.
Original M Bio articles on compounds, testing, and laboratory methods.
Showing 43 of 43 stories
How to check a lab report ID
A report ID is only proof if the issuing lab confirms it. A step-by-step way to verify one without trusting the seller's copy.
How to read a COA
A certificate of analysis is only useful if you know which line answers which question. A field-by-field walk through.
Purity vs net peptide content
Two numbers that are often confused. One describes how clean the peptide is. The other describes how much of the powder is peptide.
Storage of sealed powder
Temperature, light, moisture, and records. How sealed lyophilized material is typically kept in a laboratory.
What lyophilized powder means
Why research peptides ship as a dry cake, what freeze-drying does, and why appearance alone tells you very little.
What third-party testing means, and what it does not prove
"Third-party tested" is a common label. Here is what it actually establishes, and the questions it leaves open.
Research use, intended use, and institutional responsibility
What an RUO label establishes, and which decisions still belong to the research institution.
Residual solvents: the questions a purity percentage leaves open
How to assess a solvent panel, reporting limit, and lot-specific result without confusing it with HPLC purity.
Endotoxin testing: method, interference, and reporting limits
What an endotoxin result answers, why assay suitability matters, and how it differs from sterility.
Reading an HPLC trace beyond the headline percentage
A practical walk through peaks, integration, detector response, and the limits of area purity.
Batch traceability from supplier document to experiment
How to connect a received vial, an original report, and the experimental record without losing provenance.
Cold-chain shipping: evidence before reassurance
Why packaging, temperature history, and material-specific stability data need to be reviewed together.
Research grade and pharmaceutical quality are different claims
Why a purity percentage cannot stand in for a manufacturing system, approved formulation, or intended use.
Evaluating a supplier: a checklist built around evidence
Assess original reports, lot relationships, technical answers, and the limits of vendor claims.
Peptide stability: what can change between receipt and analysis
A framework for evaluating chemical change, physical loss, and the evidence behind a storage statement.
Reconstitution planning for laboratory experiments
Solvent compatibility, concentration records, and controls before a lyophilized material becomes an assay stock.
Peptide bonds: chemistry that constrains molecular shape
How the peptide backbone connects amino acids and why that connection matters to structure and analysis.
Why amino-acid sequence matters to peptide function
Sequence, stereochemistry, modifications, and the controls needed to connect structure with an observed effect.
Solid-phase and solution-phase peptide synthesis
What the manufacturing approach changes, and why the route name does not replace product testing.
Research peptides: a primer on molecules, models, and evidence
A starting point for understanding peptide materials without confusing research tools with approved medicines.
The GH/IGF-1 axis: a feedback system, not one measurement
How to distinguish hormone release, circulating IGF-1, and local tissue signaling in research.
IGF-1 signaling: choosing a readout that answers the question
Receptor activation, downstream pathways, and why one phosphorylation result is not an entire biological outcome.
PT-141 and melanocortin receptors: reading the model correctly
Receptor pharmacology, experimental context, and the limits of extrapolating a central signaling observation.
Epithalon and telomerase: what a cell-culture finding establishes
An evidence-focused look at telomerase activity, telomere measurements, and claims about lifespan.
Tesamorelin: a GHRH analogue across different evidence levels
How receptor biology, hormonal endpoints, and population-specific clinical research fit together.
Sermorelin and GHRH fragments: identity before comparison
Why the exact fragment, terminal chemistry, model, and sampling strategy matter in GH-pathway studies.
CJC-1295 and ipamorelin: two pathways need separate evidence
How to distinguish analogue identity, single-agent findings, and claims about a combination.
NAD+ research: redox state, location, and measurement
Why NAD+, NADH, total abundance, and cellular compartment need to be distinguished.
Peptide testing: how HPLC, mass spectrometry, and content assays fit together
A map of analytical questions that should remain separate even when they appear on one certificate.
Metabolic peptides: comparing single, dual, and triple agonism
A framework for reading an expanding field without ranking compounds by receptor count alone.
GLP-1 receptor binding and signaling are separate measurements
What structural biology, binding assays, cAMP, and receptor trafficking each contribute.
Incretin mimetics: choosing the right laboratory model
Why glucose conditions, receptor expression, and experimental scale change the question being answered.
Semaglutide and tirzepatide: comparing research questions
Receptor profiles, assay context, and the difference between mechanistic and clinical comparisons.
Tirzepatide: dual receptor activity does not mean equal activity
Receptor selectivity, signaling bias, and the controls behind a dual-agonist interpretation.
Retatrutide: reading triple-agonist evidence in layers
How discovery pharmacology and a phase 2 trial answer different questions about the same molecule.
Semaglutide: a guide to the discovery, structural, and clinical literature
Three evidence levels that should be connected carefully rather than treated as interchangeable proof.
GLP-1 agonists: from receptor signal to metabolic hypothesis
A map of evidence needed to connect cellular signaling with an integrated metabolic response.
Connective-tissue research: what a tendon or ligament model can show
Separate cellular migration, matrix measurements, histology, and mechanical function before interpreting repair claims.
GHK-Cu and collagen: distinguish synthesis, accumulation, and structure
What fibroblast experiments can tell us about matrix biology, and which outcomes need separate measurements.
BPC-157 and vascular research: markers are not the whole mechanism
How to read endothelial assays, VEGFR2-related findings, and claims about new-vessel formation.
GHK-Cu across fibroblast and tissue models
Why a matrix-related response in culture and a result in an experimental wound answer different questions.
TB-500 and thymosin beta-4: verify the exact molecule
Full-length peptide, actin-binding-domain fragments, and why names cannot substitute for structural identity.
BPC-157: how to read a preclinical evidence base
A structured approach to mechanism papers, tissue endpoints, replication, and the limits of translation.